Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
- Sponsor
- Khon Kaen University
- Study ID
- NCT01724385
- Phase
- PHASE4
- Status
- Completed
Conditions
- Proliferative Diabetic Retinopathy
- Vitreous Hemorrhage
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- intravitreal injection of bevacizumab — DRUGintravitreal injection of bevacizumab
Study Details
To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).
Key Dates
- First listed
- Nov 9, 2012
- Start date
- Aug 31, 2012
- Status verified
- Apr 2013
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: intravitreal bevacizumab injectionintravitreal injection of bevacizumab 1.25 mg
Primary Outcome Measure
The percentage of eyes that vitreous hemorrhage has been completely resolved [ Time Frame: 12 months ]